B+
Bull case
30%
Probability
Target price
$125.00
+24.2% vs current
ABT
Abbott LaboratoriesDNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
52%
Probability
Target price
$114.00
+13.2% vs current
B-
Bear case
18%
Probability
Target price
$85.00
-15.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+57.0
Score
AI commentary
News tone is strongly positive following the Q2 beat and raised EPS guidance. Trusted coverage reported an initial premarket gain, but the precise full-session reaction and post-print analyst revisions are not consistently available. Social coverage is absent, so confidence rests primarily on the company release, SEC filing context, and earnings reporting.
RankAlpha Sentiment Codex - 2026-07-17
Open post-earnings memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-07-16eventQ2 beat and higher EPS outlookMedium impact
Abbott reported Q2 sales of $12.593 billion, adjusted diluted EPS of $1.31 versus a reported $1.28 consensus, reaffirmed 2026 comparable-sales growth of 6.5%-7.5%, and raised adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58. The results were filed in the July 16 8-K and supported by Abbott's investor release. [#SEC-8K-2026-07-16]
2026-10-15catalystPost-earnings pullback riskMedium impact
The positive print has already generated a strong market reaction, increasing the risk that elevated expectations lead to profit-taking. Nutrition comparable sales remained down 3.6%, and the company cited lower volumes and strategic pricing actions.
2027-07-17catalystSecond-half Libre Duo and TECTONIC executionMedium impact
Abbott's July 16 company release identified the May CE Mark for Libre Duo and April completion of enrollment in the TECTONIC pivotal trial. The forward-looking monitoring question is whether these disclosed product and clinical milestones translate into second-half commercialization and regulatory progress. [#SEC-8K-2026-07-16]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology